Your browser is no longer supported. Please, upgrade your browser.
Settings
MESO Mesoblast Limited daily Stock Chart
MESO [NASD]
Mesoblast Limited
Index- P/E- EPS (ttm)-0.89 Insider Own- Shs Outstand116.50M Perf Week26.63%
Market Cap1.79B Forward P/E135.73 EPS next Y0.11 Insider Trans- Shs Float115.63M Perf Month43.28%
Income-97.00M PEG- EPS next Q-0.25 Inst Own2.90% Short Float2.84% Perf Quarter-19.64%
Sales16.40M P/S109.25 EPS this Y18.90% Inst Trans14.70% Short Ratio5.19 Perf Half Y18.02%
Book/sh4.62 P/B3.23 EPS next Y140.70% ROA-13.80% Target Price18.38 Perf Year145.96%
Cash/sh0.90 P/C16.59 EPS next 5Y48.80% ROE-18.70% 52W Range3.12 - 21.28 Perf YTD102.58%
Dividend- P/FCF- EPS past 5Y13.10% ROI-9.80% 52W High-29.84% Beta3.84
Dividend %- Quick Ratio1.30 Sales past 5Y10.20% Gross Margin- 52W Low378.51% ATR0.88
Employees102 Current Ratio1.30 Sales Q/Q-92.40% Oper. Margin- RSI (14)57.29 Volatility6.72% 5.14%
OptionableYes Debt/Eq0.19 EPS Q/Q-283.80% Profit Margin- Rel Volume0.38 Prev Close15.28
ShortableYes LT Debt/Eq0.12 EarningsAug 26 AMC Payout- Avg Volume632.59K Price14.93
Recom2.00 SMA2021.88% SMA5012.40% SMA20026.81% Volume240,819 Change-2.29%
Oct-22-20Initiated RBC Capital Mkts Sector Perform $12
Aug-14-20Reiterated Maxim Group Buy $16 → $22
May-28-20Reiterated H.C. Wainwright Buy $14 → $21
Jan-31-19Resumed H.C. Wainwright Buy $6.50
Mar-22-18Downgrade Credit Suisse Neutral → Underperform
Feb-28-18Reiterated Cantor Fitzgerald Buy $20 → $23
Aug-31-17Initiated Oppenheimer Outperform $16
Jun-08-17Initiated Cantor Fitzgerald Buy
Nov-28-20 11:00PM  
02:00PM  
Nov-27-20 01:07PM  
01:00PM  
Nov-26-20 09:03AM  
06:20AM  
Nov-25-20 10:23PM  
11:35AM  
11:00AM  
Nov-24-20 08:28PM  
07:00PM  
04:25PM  
04:00PM  
01:35PM  
01:00PM  
12:00PM  
11:30AM  
06:20AM  
Nov-23-20 11:00PM  
01:27PM  
01:10PM  
12:00PM  
11:45AM  
11:00AM  
06:25AM  
Nov-22-20 12:32AM  
Nov-21-20 01:06PM  
Nov-20-20 07:06PM  
11:20AM  
10:17AM  
Nov-19-20 05:40PM  
05:36PM  
05:21PM  
05:12PM  
04:19PM  
06:20AM  
Nov-18-20 10:00PM  
09:44PM  
09:15PM  
07:43PM  
05:45PM  
05:00PM  
11:30AM  
11:00AM  
Nov-17-20 05:10PM  
03:45PM  
12:00PM  
11:45AM  
11:00AM  
Nov-16-20 10:45PM  
09:45PM  
06:20AM  
Nov-14-20 04:30PM  
12:58PM  
07:33AM  
Nov-13-20 02:00PM  
01:00PM  
12:30PM  
12:00PM  
Nov-12-20 03:30PM  
02:30PM  
Nov-11-20 06:41PM  
05:15PM  
05:00PM  
04:35PM  
04:07PM  
11:50AM  
11:30AM  
10:30AM  
10:00AM  
07:31AM  
06:00AM  
Nov-10-20 03:00PM  
01:45PM  
12:22PM  
12:10PM  
11:30AM  
06:20AM  
Nov-09-20 11:30PM  
06:20AM  
Nov-07-20 10:18PM  
Nov-06-20 07:40PM  
07:15PM  
Nov-05-20 11:30AM  
11:00AM  
Nov-04-20 09:30PM  
08:30PM  
06:40PM  
06:35PM  
06:00PM  
12:30PM  
12:00PM  
Nov-03-20 04:30PM  
04:29PM  
03:50PM  
01:35PM  
01:00PM  
Nov-02-20 06:30AM  
Oct-31-20 04:09PM  
Oct-30-20 08:24PM  
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grunenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.